ENDRA Life Sciences Inc.
NDRA
$3.98
$0.529915.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 38.24% | -22.93% | -11.78% | -12.31% | -16.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.82% | -35.54% | -24.21% | -21.75% | -20.04% |
| Operating Income | -2.82% | 35.54% | 24.21% | 21.75% | 20.04% |
| Income Before Tax | -14.39% | 25.83% | 21.79% | 25.41% | 23.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.39% | 25.83% | 21.79% | 25.41% | 23.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.39% | 25.83% | 21.79% | 25.41% | 23.67% |
| EBIT | -2.82% | 35.54% | 24.21% | 21.75% | 20.04% |
| EBITDA | -3.59% | 35.30% | 24.07% | 21.88% | 20.40% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |